LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

79.53 2.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.83

Max

79.54

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-252M -129M
Pardavimai	-295M 157M
Pelnas, tenkantis vienai akcijai	-0.613
Pelno marža	-82.062
Darbuotojai	1,069
EBITDA	-245M -94M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+10.2% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.3B 13B
Ankstesnė atidarymo kaina	77
Ankstesnė uždarymo kaina	79.53

Naujienos nuotaikos

By Acuity

50%

153 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-19 17:29; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025-12-19 16:47; UTC

Pagrindinės rinkos jėgos

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025-12-19 16:10; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025-12-20 19:00; UTC

Uždarbis

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

2025-12-19 22:33; UTC

Uždarbis

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025-12-19 22:19; UTC

Uždarbis

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-19 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 21:44; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 21:38; UTC

Uždarbis

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025-12-19 21:00; UTC

Rinkos pokalbiai

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025-12-19 20:23; UTC

Rinkos pokalbiai

Oil Futures End Down Week on Up Note -- Market Talk

2025-12-19 20:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025-12-19 18:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025-12-19 18:00; UTC

Rinkos pokalbiai

Uždarbis

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025-12-19 17:41; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025-12-19 17:24; UTC

Rinkos pokalbiai

Uždarbis

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-19 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-19 16:29; UTC

Uždarbis

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025-12-19 16:20; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025-12-19 16:19; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025-12-19 16:18; UTC

Įsigijimai, susijungimai, perėmimai

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025-12-19 16:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-19 16:16; UTC

Rinkos pokalbiai

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025-12-19 16:05; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 16:04; UTC

Įsigijimai, susijungimai, perėmimai

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025-12-19 15:37; UTC

Rinkos pokalbiai

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

2025-12-19 15:21; UTC

Rinkos pokalbiai

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

2025-12-19 15:09; UTC

Rinkos pokalbiai

Gold Flat But Set for Weekly Gains -- Market Talk

2025-12-19 15:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

10.2% į viršų

12 mėnesių prognozė

Vidutinis 87.69 USD 10.2%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

Pirkti

Laikyti

Parduoti

Remiantis 18 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

153 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.